Articles On Paradigm Biopharmaceuticals (ASX:PAR)

New Zealand’s medicines regulator has recommended the country fall in line with Australia’s new codeine restrictions, and pharmaceutical companies are backing the decision. Yesterday, Medsafe recommended that all medications containing code...

CSL Limited (ASX: CSL) will go down as one of the greatest growth stories of all time. The company has been unshakeable in its ability to deliver consistent earnings growth and shareholder value for more than 2 decades. But for many inves...

With populations around the world getting older and chronic disease burden increasing, demand for healthcare services continues to increase. I expect this trend to continue for several decades, which I feel makes the healthcare sector a gr...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has gone gangbusters, soaring more than 20% in the past 5 days, before dipping back slightly in yesterday’s trade to close down 1.87%. Paradigm is a late stage ASX-listed biotechn...

I think the mid cap space is a great place to look for buy and hold investment ideas. This is because I believe there are a good number of shares that have the potential to grow strongly over the next decade, potentially generating outsize...

Paradigm is repurposing the drug Pentosan Polysulfate Sodium (PPS) under the name ZILOSUL®.

The S&P/ASX 200 index has recovered from a spot of late morning weakness and is pushing higher in afternoon trade. At the time of writing the benchmark index is up a solid 0.4% to 6,795.4 points. Four shares that are climbing more than...

The Alcidion Group Ltd (ASX: ALC) share price has been a positive performer on Tuesday. In morning trade the healthcare technology company’s shares were up 8% to 20.5 cents at one stage. Why did the Alcidion share price surge higher? Inves...

Paradigm is repurposing the drug Pentosan Polysulfate Sodium (PPS) under the name ZILOSUL®.

Australia’s health care industry is one of the fastest growing industries in the country that is making substantial progress driven by new technological advancements. The country’s government is injecting billions of dollars into modernisin...

The Novita Healthcare Ltd (ASX: NHL) share price is down 7% to 9.1 cents today, but up around 8x from 1.1 cents on October 23 after the biotech handed investors some big news. On October 24 hardly known Novita told investors its TALi Detec...

In afternoon trade the S&P/ASX 200 index has given back its morning gains and dropped lower. At the time of writing the benchmark index is trading 0.2% lower at 6,714.3 points. Four shares that have not let that hold them back are list...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price was on form again on Thursday. The biopharmaceutical company’s shares pushed 4% higher to $2.93 on the day of its annual general meeting. This latest gain means the Paradigm share...

The biotech gained up to 5% by lunch on confirming FY20 milestones, including an early-2020 filing with the US FDA for an OA drug.

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

The Next Science Ltd (ASX: NXS) share price has slipped 5% to $2.52 today but investors shouldn’t be disheartened as the stock is still up 150% from its April 2019 $1 per share initial public offer price.  For the quarter ending September...

The Novita Healthcare Ltd (ASX: NHL) share price is now up around 4.5x or 350% since last week. That’s not a typo either as the early learning childhood technology business reported that its TALi Detect platform could be delivered via the...

The S&P/ASX 200 index is on course to start the week on a positive note. In afternoon trade the benchmark index is up 0.15% to 6,749.7 points. Four shares climbing more than most today are listed below. Here’s why they are storming hig...

It has been a very positive end to the week for the S&P/ASX 200 index. In afternoon trade the benchmark index is up a solid 0.65% to 6,737 points. Four shares that have climbed more than most today are listed below. Here’s why they are...

The IRB has followed the FDA in approving the submission to treat 10 ex NFL players with Paradigm’s trial drug Zilosul.

Paradigm Biopharmaceuticals (ASX: PAR) has been given the go-ahead by US regulators to treat 10 former NFL players with its pentosan polysulfate sodium (iPPS) drug, otherwise known as Zilosul. Following the successful US Food and Drug Admin...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has gone gangbusters in 2019 as wild investor excitement mounts over its Zilosul drug’s commercial potential. The biotech now has a market value around $516 million despite posting...

The Polynovo Ltd (ASX: PNV) share price is up 7% to $2.43 this lunchtime despite the biotech not releasing any specific news to the market. On September 23 the little-known surgical material business joined the S&P/ ASX200 (ASX: XJO) in...

The Orthocell Ltd (ASX: OCC) share price is up 25% to 50 cents today after the regenerative medicine researcher announced trial results showed its medical device CelGro® had helped quadriplegics regain arm and hand functions.  CelGro® is r...

Health care, being the dynamic sector, keep investors on their toes before injecting their funds. Vigilance to information is an important criterion that allows investors and market enthusiasts to capitalise money in the stocks. Variables p...

Massive legal settlements in the US have highlighted the scourge of opioid abuse, but Australian producer Palla Pharma is confident the drug class will remain the world's foremost pain medication. Meanwhile, Paradigm Pharmaceuticals present...

The All Ordinaries index was a strong performer on Tuesday, rising by a solid 0.8% to 6,853 points. This strong gain means the index is now trading close to its all-time high. Unsurprisingly, this positive form means a number of shares are...

Mesoblast limited (ASX: MSB) shares are locked in a trading halt today with the regenerative medicine business reportedly seeking to raise another $75 million according to news reports in the Australian Financial Review. Mesoblast has often...

Headlines are being made in the US today with a Republican Congressman expected to plead guilty to insider trading charges brought by the US securities regulator the SEC. Making the case unusual is that the micro-cap biotech in question is...

It's been 25 years since the Canberra Raiders have won a premiership. Sadly they knocked out my Bunnies on Friday night, but if we were going to lose to anyone I'm glad it was the Green Machine. Let's just hope they spank the Roosters on Su...

You may have heard about an opioid crisis over in the US; it was declared a public health emergency in 2017 amid 130 deaths every day from opioid-related drug overdoses and 2.1 million people with an opioid use disorder. In Australia, the p...

I’ve not bought many new companies on the local sharemarket over the last 12 months as most of any research efforts are directed towards the US these days, however, there are a few small-cap businesses on the local market worth watching. ...

The company’s data has been published in the peer-reviewed international scientific journal PLoS One

Health care industry Australian health care industry is not just on a strong growth path but also competes on the global scale. Health Care comprises of a dynamic sector including pharmaceuticals, medical devices, health insurance and hospi...

In afternoon trade the S&P/ASX 200 index is on course to start the week with a small gain. At the time of writing the benchmark index is up 0.15% to 6,726 points. Four shares that are climbing more than most today are listed below. Her...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Paradigm Biopharmaceuticals (ASX: PAR) claims it has made a “ground-breaking discovery” as part of its ongoing development of pentosan polysulfate sodium (PPS), an antithrombotic agent that reduces joint pain. The biotech company conducted...

The company’s data has been published in the peer-reviewed international scientific journal PLoS One

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has rocketed over 2019 as excitement mounts over the biotech researcher’s potential to commercialise drugs designed to treat inflammatory conditions such as osteoarthritis. On Septe...

The Bionomics Ltd (ASX: BNO) share price shot up 41% today after the biotechnology researcher announced its PTSD drug labelled BNC210 had delivered positive results from a clinical trial. In five healthy male volunteers it was found that t...

The notion of ‘everything old is new again’ applies not just to fickle fashion trends, but to drug development as well. Drug reformulations are all the rage and it’s not such a bad thing. Think of Paradigm Biopharmaceuticals (ASX:PAR) with...

Medical company Paradigm Biopharmaceuticals (ASX: PAR) has received clearance from the US Food and Drug Administration for an investigational new drug (IND) application relating to pentosan polysulfate sodium (PPS) for the treatment of knee...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is down 7% to $1.95 today, despite the biotech researcher today telling the market that its first ‘investigational new drug’ (IND) application had been approved by the US healthcar...

The Mesoblast limited (ASX: MSB) share price is up 17% to $1.70 today after the regenerative medicine business announced it has agreed a funding source and ‘strategic partnership” with German pharmaceutical business Grünenthal. It’s not ha...

FDA Clearance means validation of Paradigm’s safety data, the finished product’s quality and confirmation of an unmet medical need.

Paradigm Biopharmaceuticals Limited (ASX: PAR) has reported that its first IND (Investigational New Drug) application has been cleared by the US FDA within the 30-day review period. As per CEO Paul Rennie, this clearance demonstrates the ne...

The Mesoblast Limited (ASX: MSB) share price has been amongst the best performers on the All Ordinaries index on Tuesday. In morning trade the allogeneic cellular medicines developer’s shares surged a sizeable 17% higher to $1.70 following...

The Opthea Ltd (ASX: OPT) share price is up 2.4% to $3.83 today after the eye disease treatment biotech updated investors on progress over its Phase 2b clinical trial into its OPT-302 with ranibizumab (Lucentis®) treatment compared to rani...

Australia has a robust health care system, jointly operated by the federal, state and local governments, and is labeled as one of the best in the world. For investors, health care stands among the top few sectors, and is the safest sectors...

In afternoon trade the S&P/ASX 200 index has failed to follow the lead of U.S. markets and is trading lower. At the time of writing the benchmark index is down 0.1% to 6,494.8 points. Four shares that have not let that hold them back t...